What the FDA labels say about taking them together
Dolutegravir and efavirenz
Dolutegravir's FDA label of May 22, 2026 names efavirenz in its drug interactions section; the efavirenz label PlainMeds reads does not name dolutegravir. The dolutegravir label: “Adjust dose of TIVICAY to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of TIVICAY or TIVICAY PD to twice daily. …”
Check it at the source: the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY); the efavirenz FDA label on DailyMed (effective March 31, 2024, Cipla USA Inc.).
What does the dolutegravir label say about efavirenz?
Dolutegravir label, drug interactionsConcomitant Drug Class/Drug Name: Non-nucleoside reverse transcriptase inhibitor: Efavirenz a; Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Adjust dose of TIVICAY to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of TIVICAY or TIVICAY PD to twice daily (Tables,, and). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. b
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
What does the efavirenz label say about dolutegravir?
Efavirenz's label (effective March 31, 2024) does not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Efavirenz), Cipla USA Inc., effective March 31, 2024 (SPL set 92603fa5-7a2c-4bfb-9a70-aadb4fba952c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dolutegravir | Efavirenz | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $77.64 per tablet 50 mg tablet | $1.28 per tablet 600 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once